Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOKGet Free Report) have received a consensus rating of “Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $21.29.

Several brokerages recently issued reports on STOK. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th.

Get Our Latest Research Report on Stoke Therapeutics

Stoke Therapeutics Stock Up 2.0 %

Shares of NASDAQ:STOK opened at $11.49 on Monday. The stock’s 50 day moving average is $12.21 and its 200-day moving average is $13.20. Stoke Therapeutics has a twelve month low of $4.09 and a twelve month high of $17.58. The firm has a market capitalization of $608.59 million, a price-to-earnings ratio of -5.47 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. Equities research analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. The trade was a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. The trade was a 38.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 in the last three months. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in Stoke Therapeutics during the second quarter worth about $29,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $123,000. Intech Investment Management LLC bought a new position in Stoke Therapeutics in the 3rd quarter worth approximately $160,000. The Manufacturers Life Insurance Company grew its stake in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new stake in Stoke Therapeutics during the 3rd quarter valued at $192,000.

About Stoke Therapeutics

(Get Free Report

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

See Also

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.